Literature DB >> 21320226

Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users.

Kate M Morefield1, Michael Keane, Peter Felgate, Jason M White, Rodney J Irvine.   

Abstract

AIMS: To improve our understanding of the pharmacology of 'ecstasy' in recreational environments; in particular, to describe the composition of ecstasy pills, patterns of ecstasy use and the relationship between dose of 3,4-methylendioxymethamphetamine (MDMA) and resulting plasma concentrations. DESIGN, SETTING AND PARTICIPANTS: A naturalistic observational study of 56 experienced 'ecstasy' users in recreational settings in Australia. MEASUREMENTS: Drug use patterns (number of pills consumed, other drugs consumed). drug content of pills and resultant plasma concentrations of MDMA and related drugs were assessed by gas chromatography/mass spectrometry (GC/MS).
FINDINGS: Ecstasy pills generally contained MDMA, but this was often combined with other drugs such as 3,4-ethylendioxyethylamphetamine (MDEA) and methamphetamine. The dose of MDMA per pill ranged from 0 to 245 mg and users consumed from one-half to five pills, with the total dose consumed ranging up to 280 mg. Plasma concentrations of MDMA increased with number of pills consumed and cumulative MDMA dose. Use of larger numbers of pills was associated with extended exposure to the drug.
CONCLUSIONS: MDMA is the major active drug in ecstasy pills, but there is a high degree of variation in doses. Use of multiple pills over the course of one session is common and results in a sustained increase in MDMA plasma concentrations over a number of hours. This is likely to lead to a much greater exposure of the brain to MDMA than would be predicted from controlled single-dose pharmacokinetic studies.
© 2011 The Authors, Addiction © 2011 Society for the Study of Addiction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320226     DOI: 10.1111/j.1360-0443.2011.03399.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  17 in total

1.  Nanoparticle based galectin-1 gene silencing, implications in methamphetamine regulation of HIV-1 infection in monocyte derived macrophages.

Authors:  Jessica L Reynolds; Wing Cheung Law; Supriya D Mahajan; Ravikumar Aalinkeel; Bindukumar Nair; Donald E Sykes; Ken-Tye Yong; Rui Hui; Paras N Prasad; Stanley A Schwartz
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-12       Impact factor: 4.147

2.  Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Authors:  Melanie Mueller; Amy K Goodwin; Nancy A Ator; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

3.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: Lost in translation.

Authors:  Cédric M Hysek; Yasmin Schmid; Anna Rickli; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

4.  Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series.

Authors:  Jennifer J E Nicol; Mark C Yarema; Graham R Jones; Walter Martz; Roy A Purssell; Judy C MacDonald; Ian Wishart; Monica Durigon; Despina Tzemis; Jane A Buxton
Journal:  CMAJ Open       Date:  2015-01-13

5.  MDMA effects consistent across laboratories.

Authors:  Matthew G Kirkpatrick; Matthew J Baggott; John E Mendelson; Gantt P Galloway; Matthias E Liechti; Cédric M Hysek; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-03-15       Impact factor: 4.530

6.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.

Authors:  April Rolle; Mai Takematsu; Robert Hoffman
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 7.  Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

8.  Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart.

Authors:  A M Peiró; M Farré; P N Roset; M Carbó; M Pujadas; M Torrens; J Camí; R de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2012-11-10       Impact factor: 4.530

9.  Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification.

Authors:  Stephen L Thornton; Roy R Gerona; Christian A Tomaszewski
Journal:  J Med Toxicol       Date:  2012-09

10.  Behavioral effects and pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboons.

Authors:  Amy K Goodwin; Melanie Mueller; Courtney D Shell; George A Ricaurte; Nancy A Ator
Journal:  J Pharmacol Exp Ther       Date:  2013-03-20       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.